Abstract:Objective: To investigate the safety and effects of pitavastatin-loaded nanoparticles eluting stent in percutaneous coronary artery stent implantation in experimental porcine models. Methods: The authors developed a novel drug eluting stent (DES) by using nanoparticles, which was made of biological absorbable FLGA material that could be coated on stent by using positive ion electroplating and coating technology. First, the human smooth muscle cells obtained from coronary artery and the human umbilical vein endothelial cells were cultured in vitro to observe the effects of statins on the cellular proliferation, which was compared with the effects of rapamycin and paclitaxel. The effects of statins-loaded nanoparticle eluting stent on intima proliferation and endothelial regeneration were then studied in vivo in experimental porcine by percutaneous coronary artery stent implantation. Results: The FLAG nanoparticles labeled by FITC were homogeneously coated on the stent by positive ion electroplating and coating technology. The results of in vitro experiment showed that approximately 40% of FITC was released from the nanoparticles within 24 hours, and all the rest was completely released after 30 days. FITC labeled nanoparticles were completely released from coating stent after 56 days. The results of in vitro experiment showed that statins could inhibit the proliferation of smooth muscle cells, but the pitavastatin exhibited the strongest inhibition effect compared with simvastatin, fluvastatin and atorvastatin (P < 0.001). Among the drugs tested, pitavastatin was the only drug that could promote the endothelial cell regeneration (P < 0.05). Moreover, pitavastatin could exert its inhibitory effect even at the concentration as low as 0.01 μmol/L (P < 0.05). Therefore, pitavastatin was used to test the biological effect in vivo by employing statin nanoparticle coated DES in coronary artery stent implantation. The results indicate d that pitavastatin nanoparticle loaded DES could significantly reduce the intima proliferation when compared with non-drugloaded nanoparticle DES (P < 0.01). The degree of intima proliferation seen in pitavastatin nanoparticle loaded DES was quite the same as seen in Cypher stent (P > 0.05). Moreover, the inflammation, fibrosis and endothelial cell regeneration seen in pitavastatin nanoparticle loaded DES were also markedly reduced (P < 0.01). Conclusion: The pitavastatin loaded nanoparticle DES has been successfully developed. The use of this new pitavastatin loaded nanoparticle DES can significantly reduce the incidence of in-stent re-stenosis and thrombosis.

[In Vitro Study of Platelet Glycoprotein Monoclonal Antibody Eluting Stents].

In-vitro assays of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor monoclonal antibody.

Eluting Characteristics of a Platelet Glycoprotein Receptor Antibody Using a PLLA-coated Stent.

Endothelialization and In-Stent Restenosis on the Surface of Glycoprotein Iiia Monoclonal Antibody Eluting Stent

Ultrasonic Atomization and Subsequent Desolvation for Monoclonal Antibody (mab) to the Glycoprotein (GP) IIIa Receptor into Drug Eluting Stent

Layer-by-layer Assembly of Chitosan and Platelet Monoclonal Antibody to Improve Biocompatibility and Release Character of PLLA Coated Stent.

EVALUATION OF INTIMAL HYPERPLASIA AND THROMBOSIS AFTER IMPLANTATION OF PLATELET GLYCOPROTEIN IIIa MONOCLONAL ANTIBODY-ELUTING STENT IN NEW ZEALAND WHITE RABBIT AORTA OR ILIAC ARTERIES

Immobilization of CD34 Antibodies onto 316L Stainless Steel and in vitro Cytocompatibility

Direct Adsorption of Anti-CD34 Antibodies on the Nano-Porous Stent Surface to Enhance Endothelialization.

Preparation of Vascular Endothelial Cadherin Loaded-Amphoteric Copolymer Decorated Coronary Stents for Anticoagulation and Endothelialization

Liposomal surface coatings of metal stents for efficient non-viral gene delivery to the injured vasculature

Preparation, characterization and in vitro anticoagulation of emodin-eluting controlled biodegradable stent coatings.

Design, preparation and performance of a novel drug-eluting stent with multiple layer coatings.

In Vivo Biocompatibility of a Plasma-Activated, Coronary Stent Coating.

[Immobilization of CD34 Antibodies Onto Ethylene-Vinyl Acetate Copolymer Coatings and in Vitro Cell Attachments].

Biodegradable Polymer Coated Emodin Eluting Stent in vitro and in vivo

Study of Novel Coating Strategy for Coronary Stents: Simutaneous Coating of VEGF and Anti- CD34 Antibody.

Study of a Novel Coating Strategy for Coronary Stents: Evaluation of Stainless Metallic Steel Coated with VEGF and Anti-Cd34 Antibody in Vitro.

A Novel Stent Coated with Antibody Against CD34 Carried by the Degradable Polymer Reduces Restenosis in Canine

The preparation of pitavastatin incorporated nanoparticle-eluting stent

Distinctive Effects of CD34- and CD133-specific Antibody-Coated Stents on Re-Endothelialization and In-Stent Restenosis at the Early Phase of Vascular Injury